Use of hormonal contraceptives and smoking cessation: A preliminary report

Alicia M. Allen, Samantha Carlson, Lynn E. Eberly, Dorothy Hatsukami, Megan E. Piper

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Although endogenous sex hormones influence smoking-related outcomes, little is known about the effect of exogenous sex hormones. Therefore, the goal of this preliminary study was to examine differences in withdrawal symptoms and cessation between women using hormonal contraceptives (HC), women not using hormonal contraceptives (no-HC) and men. Utilizing data from two recently completed smoking cessation randomized clinical trials, we selected participants who were between the ages of 18–35 years old. Participants were classified based on use of hormonal contraceptives and gender, then matched based on pharmacotherapy randomization assignment and baseline cigarettes per day. Participants provided self-reported assessments on withdrawal, craving and negative affect, and smoking status was assessed for 52 weeks after quit date. Participants (N = 130) were 28.7 ± 0.4 years old and smoked 16.8 ± 0.6 cigarettes/day. Compared to both no-HC and men, the HC group had significantly greater withdrawal one week prior to the quit date, on the quit date and one week after the quit date. During the first week of attempted abstinence, craving declined in HC and in men, but increased in no-HC. At end of treatment, the HC group was at 3.73 times higher odds of being abstinent compared to men (95% confidence interval: 1.12–12.40). There were no group differences in abstinence rates at Week 26 or 52. These data suggest that HC users may experience more adverse levels of withdrawal, though may be more likely to achieve short-term abstinence. Future research is needed to replicate our observations and explore mechanisms of action.

LanguageEnglish (US)
Pages236-242
Number of pages7
JournalAddictive Behaviors
Volume76
DOIs
StatePublished - Jan 1 2018

Fingerprint

Smoking Cessation
Contraceptive Agents
Gonadal Steroid Hormones
Tobacco Products
Smoking
Drug therapy
Substance Withdrawal Syndrome
Random Allocation
Randomized Controlled Trials
Confidence Intervals
Drug Therapy

Keywords

  • Cessation
  • Craving
  • Gender/sex differences
  • Hormones
  • Withdrawal
  • Women

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial

Cite this

Use of hormonal contraceptives and smoking cessation : A preliminary report. / Allen, Alicia M.; Carlson, Samantha; Eberly, Lynn E.; Hatsukami, Dorothy; Piper, Megan E.

In: Addictive Behaviors, Vol. 76, 01.01.2018, p. 236-242.

Research output: Contribution to journalArticle

Allen, Alicia M. ; Carlson, Samantha ; Eberly, Lynn E. ; Hatsukami, Dorothy ; Piper, Megan E. / Use of hormonal contraceptives and smoking cessation : A preliminary report. In: Addictive Behaviors. 2018 ; Vol. 76. pp. 236-242.
@article{9b54589e2a6c4b2db430080ae8fecb88,
title = "Use of hormonal contraceptives and smoking cessation: A preliminary report",
abstract = "Although endogenous sex hormones influence smoking-related outcomes, little is known about the effect of exogenous sex hormones. Therefore, the goal of this preliminary study was to examine differences in withdrawal symptoms and cessation between women using hormonal contraceptives (HC), women not using hormonal contraceptives (no-HC) and men. Utilizing data from two recently completed smoking cessation randomized clinical trials, we selected participants who were between the ages of 18–35 years old. Participants were classified based on use of hormonal contraceptives and gender, then matched based on pharmacotherapy randomization assignment and baseline cigarettes per day. Participants provided self-reported assessments on withdrawal, craving and negative affect, and smoking status was assessed for 52 weeks after quit date. Participants (N = 130) were 28.7 ± 0.4 years old and smoked 16.8 ± 0.6 cigarettes/day. Compared to both no-HC and men, the HC group had significantly greater withdrawal one week prior to the quit date, on the quit date and one week after the quit date. During the first week of attempted abstinence, craving declined in HC and in men, but increased in no-HC. At end of treatment, the HC group was at 3.73 times higher odds of being abstinent compared to men (95{\%} confidence interval: 1.12–12.40). There were no group differences in abstinence rates at Week 26 or 52. These data suggest that HC users may experience more adverse levels of withdrawal, though may be more likely to achieve short-term abstinence. Future research is needed to replicate our observations and explore mechanisms of action.",
keywords = "Cessation, Craving, Gender/sex differences, Hormones, Withdrawal, Women",
author = "Allen, {Alicia M.} and Samantha Carlson and Eberly, {Lynn E.} and Dorothy Hatsukami and Piper, {Megan E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.addbeh.2017.08.003",
language = "English (US)",
volume = "76",
pages = "236--242",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Use of hormonal contraceptives and smoking cessation

T2 - Addictive Behaviors

AU - Allen, Alicia M.

AU - Carlson, Samantha

AU - Eberly, Lynn E.

AU - Hatsukami, Dorothy

AU - Piper, Megan E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although endogenous sex hormones influence smoking-related outcomes, little is known about the effect of exogenous sex hormones. Therefore, the goal of this preliminary study was to examine differences in withdrawal symptoms and cessation between women using hormonal contraceptives (HC), women not using hormonal contraceptives (no-HC) and men. Utilizing data from two recently completed smoking cessation randomized clinical trials, we selected participants who were between the ages of 18–35 years old. Participants were classified based on use of hormonal contraceptives and gender, then matched based on pharmacotherapy randomization assignment and baseline cigarettes per day. Participants provided self-reported assessments on withdrawal, craving and negative affect, and smoking status was assessed for 52 weeks after quit date. Participants (N = 130) were 28.7 ± 0.4 years old and smoked 16.8 ± 0.6 cigarettes/day. Compared to both no-HC and men, the HC group had significantly greater withdrawal one week prior to the quit date, on the quit date and one week after the quit date. During the first week of attempted abstinence, craving declined in HC and in men, but increased in no-HC. At end of treatment, the HC group was at 3.73 times higher odds of being abstinent compared to men (95% confidence interval: 1.12–12.40). There were no group differences in abstinence rates at Week 26 or 52. These data suggest that HC users may experience more adverse levels of withdrawal, though may be more likely to achieve short-term abstinence. Future research is needed to replicate our observations and explore mechanisms of action.

AB - Although endogenous sex hormones influence smoking-related outcomes, little is known about the effect of exogenous sex hormones. Therefore, the goal of this preliminary study was to examine differences in withdrawal symptoms and cessation between women using hormonal contraceptives (HC), women not using hormonal contraceptives (no-HC) and men. Utilizing data from two recently completed smoking cessation randomized clinical trials, we selected participants who were between the ages of 18–35 years old. Participants were classified based on use of hormonal contraceptives and gender, then matched based on pharmacotherapy randomization assignment and baseline cigarettes per day. Participants provided self-reported assessments on withdrawal, craving and negative affect, and smoking status was assessed for 52 weeks after quit date. Participants (N = 130) were 28.7 ± 0.4 years old and smoked 16.8 ± 0.6 cigarettes/day. Compared to both no-HC and men, the HC group had significantly greater withdrawal one week prior to the quit date, on the quit date and one week after the quit date. During the first week of attempted abstinence, craving declined in HC and in men, but increased in no-HC. At end of treatment, the HC group was at 3.73 times higher odds of being abstinent compared to men (95% confidence interval: 1.12–12.40). There were no group differences in abstinence rates at Week 26 or 52. These data suggest that HC users may experience more adverse levels of withdrawal, though may be more likely to achieve short-term abstinence. Future research is needed to replicate our observations and explore mechanisms of action.

KW - Cessation

KW - Craving

KW - Gender/sex differences

KW - Hormones

KW - Withdrawal

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85028470008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028470008&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2017.08.003

DO - 10.1016/j.addbeh.2017.08.003

M3 - Article

VL - 76

SP - 236

EP - 242

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

ER -